they were then “switched” from the aromatase inhibitor to camizestrant, while continuing the same CDK4/6 inhibitor.

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

AstraZeneca’s drug candidate Camizestrant combined ... survival compared with the standard-of-care treatment with an aromatase inhibitor, a type of hormone therapy. The experimental drug also ...

Considering taking supplements to treat aromatase inhibitor induced arthralgia? Below is a list of common natural remedies used to treat or reduce the symptoms of aromatase inhibitor induced ...

New research reveals that breast cancer survivors who underwent chemotherapy may face long-term physical decline Learn about ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

All patients received an aromatase inhibitor and a CDK4/6 inhibitor ... patients switched to camizestrant and stayed on the CDK4/6 drug. ESR1 mutations are found in about 5% of patients at ...